FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today...
2023-03-21 16:57:51 ET Gainers: Maxpro Capital Acquisition ( JMAC ) +31% . Telesis Bio ( TBIO ) +10% . BridgeBio Pharma ( BBIO ) +4% . Hawaiian Holdings ( HA ) +2% . ProFrac Holding ( ACDC ) +2% . Losers: Adap...
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) ha...
TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate ...
Taipei City, Oct. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by ...
Cancer drugmaker Apollomics agreed to go public through a deal with SPAC Maxpro Capital Acquisition Corp. ( NASDAQ: JMAC ). JMAC ticked up 1% in premarket trading. The deal values Apollomics at a pre-money equity value of $899 million, according to a statement . Up...
– Transaction values Apollomics at pre-money equity value of $899 million – Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs –Broad pipeline of drug candidates across multiple...
News, Short Squeeze, Breakout and More Instantly...
Maxpro Capital Acquisition Corp. Company Name:
JMAC Stock Symbol:
NASDAQ Market:
FOSTER CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today...
FOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) ha...
TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate ...